Concurrent evaluation of immunosuppression and blood Herpesvirus reactivation on day 7 after ICU admission in a mixed patient population
-
By
-
Quentin Demougeot
-
Fabienne Venet
-
Guillaume Monneret
-
November 2, 2026
Clinical Scorecard: Concurrent evaluation of immunosuppression and blood Herpesvirus reactivation on day 7 after ICU admission in a mixed patient population
At a Glance
| Category | Detail |
|---|---|
| Condition | Clinical topic addressed by the source article: Concurrent evaluation of immunosuppression and blood Herpesvirus reactivation on day 7 after ICU admission in a mixed patient population |
| Key Mechanisms | ICU-acquired immunosuppression was assessed by decreased monocyte HLA-DR expression (mHLA-DR); blood reactivation was assessed by herpesvirus DNAemia. The correspondence notes that viral reactivation is commonly detected in critical illness and may reflect compromised host immune defenses. |
| Target Population | Population described in the source article. |
| Care Setting | Day-7 landmark assessment among patients still hospitalized in the ICU; this time point matches eligibility timing for IFN-γ immunoadjuvant treatment in ongoing clinical trials. |
Key Highlights
- Immunosuppression was defined as mHLA-DR below 8000 AB/C; viral reactivation required detection of DNAemia for at least one tested herpesvirus at day 7.
- At day 7, 33% of patients had at least one blood herpesvirus reactivation; 25% of that subgroup had multiple reactivations.
- Low mHLA-DR was associated with adverse outcomes, while the analysis found no such relationship for viral reactivation.
- Among immunosuppressed patients, outcomes did not differ significantly by viral reactivation status; outcomes differed by immunosuppression status within both viral-status subgroups.
- The composite endpoint was ICU-acquired infection and/or mortality by 90 days; findings were consistent in analyses of 28-day mortality and selected subgroups or alternative mHLA-DR thresholds.
Guideline-Based Recommendations
Diagnosis
- The study operationalized immunosuppression as mHLA-DR below 8000 AB/C.
- Viral reactivation required plasma quantitative PCR detection of at least one of EBV, CMV, HHV6, or HSV1 at the specified time point.
Management
Monitoring & Follow-up
Risks
- Low mHLA-DR was associated with adverse outcomes after adjustment for age, Charlson Index, and admission SOFA score.
- After accounting for immune status, the study found no clear evidence linking day-7 blood herpesvirus reactivation to poorer prognosis for secondary infection or mortality.
- The authors note that inadequate statistical power cannot be excluded, particularly given the smaller number of septic patients and subgroup analyses.
Patient & Prescribing Data
The analysis included 195 patients with both day-7 mHLA-DR and viral reactivation data: 45 IS+/VR+, 62 IS+/VR−, 20 IS−/VR+, and 68 IS−/VR−. The mixed ICU cohort included patients with sepsis, severe trauma, major surgery, and burns.
No treatment efficacy or prescribing outcomes were evaluated. The day-7 assessment was framed around the timing at which initiation of immunostimulatory therapy might be considered in clinical trials.
Clinical Best Practices
- In this cohort, adverse outcomes were associated mainly with decreased mHLA-DR rather than viral reactivation.
- Interpret the findings in light of the day-7 landmark and inclusion of patients still hospitalized in the ICU; the authors describe the analysis as exploratory and hypothesis-generating.
- Blood PCR results do not establish whether viral reactivation occurred at other sites; respiratory tract reactivation was not assessed.
Related Resources & Content
Based on findings from:
Concomitant assessment of immunosuppression and Herpesvirus reactivation in blood at Day 7 after ICU admission in a mixed population
Quentin Demougeot, Fabienne Venet, Guillaume Monneret. Critical Care, 2026.
https://link.springer.com/article/10.1186/s13054-026-06437-4
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
